Lantern Pharma's second quarter operating loss fell 25% as HARMONIC trial data improved

Lantern Pharma reported a second quarter 2026 loss from operations of $3.5 million, reflecting a 25% improvement year-over-year. While net loss widened to $7.1 million, the increase was largely due to a $3.6 million non-cash warrant expense triggered by a rise in the company's stock price. Operationally, the company spinoff its AI platform into Open Medicine AI and received EMA clearance for new clinical trials in Europe.

Key Highlights

• Median progression-free survival reached 8.9 months in the EGFR exon 21 L858R patient subgroup for the LP-300 HARMONIC trial, compared to 8.4 months for the overall cohort.
• Research and development expenses decreased 42% to $1.8 million, primarily driven by a $1.0 million reduction in clinical trial material and study costs.
• Total cash and marketable securities were approximately $7.4 million as of June 30, 2026, including $4.4 million in gross proceeds from a May financing.
• Open Medicine AI was established as a separate entity with executed commercial licenses to market the multi-agentic AI platform previously known as withZeta.ai.